Nouv Rev Fr Hematol (1978). 1988;30(5-6):443-8.
This paper summarizes results from clinical trials in Chronic Lymphocytic Leukemia with a special emphasis on our protocols, CLL 80 and CLL 85, both based on the (A, B, C) staging. The third interim analysis of the CLL 80 protocol (973 patients, 287 deaths) confirmed, in stage C patients, the effectiveness of the CHOP regimen when compared to the COP regimen; failed to show a benefit from the COP regimen when compared to chlorambucil in stage B patients; and pointed out a toxic effect on survival from a daily indefinite course of chlorambucil when compared to no treatment in stage A patients. The major question of the CLL 85 protocol was the potential benefit of the CHOP regimen in stage B patients. The first interim analysis estimated the percentage of stage B patients who reached clinical remission or stage A at 77% with the CHOP regimen versus 53% in the control group (intermittent chlorambucil-prednisone).
本文总结了慢性淋巴细胞白血病临床试验的结果，特别强调了我们基于（A、B、C）分期的CLL 80和CLL 85方案。CLL 80方案的第三次中期分析（973例患者，287例死亡）证实，在C期患者中，与COP方案相比，CHOP方案有效；在B期患者中，与苯丁酸氮芥相比，未显示COP方案有获益；并且指出在A期患者中，与不治疗相比，苯丁酸氮芥每日不定疗程对生存有不良影响。CLL 85方案的主要问题是CHOP方案在B期患者中的潜在获益。第一次中期分析估计，CHOP方案组达到临床缓解或进入A期的B期患者百分比为77%，而对照组（间歇使用苯丁酸氮芥-泼尼松）为53%。
